Method of detecting autoantibodies from patients suffering from rheumatoid arthritis, a peptide and an assaykit
CA 2892001 C · Owner: Stichting Voor De Technische Wetenschappen · Inventors: Van Venrooij, Waltherus Jacobus Wilhelmus; Drijfhout, Jan Wouter; Pruijn, Gerardus Jozef Maria
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to method of detecting autoantibodies from patients suffering from rheumatoid arthritis. To this end according to the invention, at least two peptide units are used of which at least one peptide unit comprises a part not derived from (pro)fillaggrin fibrin, fibrinogen, vimentin, cytokeratin 1 and cytokeratin 9 and which peptide unit comprises the motif XG and a peptide unit comprising the motif XnonG wherein X is a citrullin or an analogue thereof and nonG is an amino acid other than glycine.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 11, 2002 and granted July 18, 2017. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 11, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 11, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.